Nephrotic Syndrome
📧 Sign up to get email alerts when something new happens for Nephrotic Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-03-30FDA Approved: METOLAZONE — Original Application (Method Pharmaceuticals, LLC)
FDA approved METOLAZONE under an original ANDA from Method Pharmaceuticals, LLC (generic approval).
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) [Phase 2]
Phase 2 pilot study evaluating abatacept for safety and efficacy in adults and children 6+ with nephrotic syndrome due to FSGS or minimal ch…
-
FDA approval · 2021-02-26FDA Approved: SPIRONOLACTONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for spironolactone from Mylan Pharmaceuticals, resulting in changes to the product labeling as p…
-
FDA approval · 2021-02-26FDA Approved: SPIRONOLACTONE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for Accord Healthcare's generic spironolactone. This action confirms approval of modifications under…
-
FDA approval · 2021-02-19FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for Spironolactone and Hydrochlorothiazide by Prasco Laboratories, authorizing its marketing as …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-01-27FDA Approved: FUROSEMIDE — Original Application (Sagent Pharmaceuticals)
FDA approved a new generic version of furosemide from Sagent Pharmaceuticals under an original application, enabling market entry as a loop …
-
CLINICAL_TRIALS withdrawal · 2020-12-29Clinical Trial Update: Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment [Phase 3]
A Phase 3 randomized trial evaluating mycophenolate mofetil for nephrotic syndrome in children after rituximab treatment has been withdrawn.
-
FDA approval · 2020-12-22FDA Approved: FUROSEMIDE — Supplemental Application (Marlex Pharmaceuticals, Inc.)
The FDA approved a supplemental application for furosemide from Marlex Pharmaceuticals, Inc., indicating an additional/or updated approval f…
-
CLINICAL_TRIALS trial_result · 2020-07-30Clinical Trial Update: Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome [Phase 2]
Phase 2 trial comparing ofatumumab to rituximab in children with steroid- and calcineurin inhibitor-dependent idiopathic nephrotic syndrome;…
-
FDA approval · 2020-07-01FDA Approved: FUROSEMIDE — Original Application (Gland Pharma Limited)
FDA approves the original generic application for furosemide from Gland Pharma Limited.
-
FDA approval · 2020-05-31FDA Approved: FUROSEMIDE — Supplemental Application (Solco Healthcare LLC)
FDA approves a supplemental ANDA for furosemide from Solco Healthcare LLC.
-
FDA approval · 2020-05-28FDA Approved: FUROSEMIDE — Supplemental Application (Ipca Laboratories Limited)
The FDA approved Ipca Laboratories Limited's supplemental application for furosemide under an ANDA, updating the approved product.
-
FDA approval · 2020-05-04FDA Approved: TORSEMIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Torsemide from Rising Pharma Holdings, Inc. under an ANDA (ANDA078249).
-
FDA approval · 2020-05-04FDA Approved: TORSEMIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for torsemide from Teva Pharmaceuticals USA, Inc., under the Torsemide product line.
-
FDA approval · 2020-04-06FDA Approved: BUMETANIDE — Supplemental Application (NorthStar Rx, LLC)
The FDA approved a supplemental application for bumetanide submitted by NorthStar Rx, LLC.
-
FDA approval · 2020-04-06FDA Approved: BUMETANIDE — Supplemental Application (Sandoz Inc)
FDA approved Sandoz Inc's supplemental application for bumetanide (generic) under an ANDA.
-
FDA approval · 2020-02-19FDA Approved: ETHACRYNIC ACID — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith's original generic application for Ethacrynic acid, a loop diuretic.
-
FDA approval · 2019-12-12FDA Approved: BUMETANIDE — Original Application (Rising Pharma Holdings, Inc)
FDA approved an original ANDA for bumetanide from Rising Pharma Holdings, Inc, making the generic diuretic available.
-
FDA approval · 2019-11-14FDA Approved: SPIRONOLACTONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for spironolactone from Mylan Pharmaceuticals Inc., enabling continued marketing of the product and …
-
FDA approval · 2019-11-14FDA Approved: SPIRONOLACTONE — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
FDA has approved a supplemental application for spironolactone from Jubilant Cadista Pharmaceuticals Inc. under the ANDA framework.
-
FDA approval · 2019-09-06FDA Approved: ETHACRYNIC ACID — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals, Inc.'s Original Application for Ethacrynic acid, authorizing a generic version of the loop diuretic. Thi…
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome [Phase 3]
Phase 3 clinical trial exploring whether lymphocyte markers can predict response to rituximab in idiopathic nephrotic syndrome.
-
FDA approval · 2019-08-27FDA Approved: ETHACRYNIC ACID — Original Application (ScieGen Pharmaceuticals Inc)
FDA approved Ethacrynic acid from ScieGen Pharmaceuticals Inc under an Original Application (ANDA211232).
-
FDA approval · 2019-08-06FDA Approved: CHLORTHALIDONE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved the original application for chlorthalidone from Unichem Pharmaceuticals (USA), Inc., enabling a generic version of the diureti…
-
FDA approval · 2019-08-05FDA Approved: SPIRONOLACTONE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's supplemental application for spironolactone, enabling the marketing of a new generic product.